Volume 24, Issue 7 (10-2025)
JRUMS 2025, 24(7): 615-628 |
Back to browse issues page
Ethics code: IR.RUMS.REC.1401.186
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ahmadian E, Kamiab Z, Heydari S M, Jamshidi M, Abbasifard M. Prevalence of Renal Manifestations and Associated Factors in Patients with Systemic Lupus Erythematosus Referred to the Rheumatology Clinic of Rafsanjan in 2022:
A Descriptive Study. JRUMS 2025; 24 (7) :615-628
URL: http://journal.rums.ac.ir/article-1-7525-en.html
URL: http://journal.rums.ac.ir/article-1-7525-en.html
Rafsanjan University of Medical Sciences
Abstract: (22 Views)
Background and Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects various organs of the body, including the kidneys. This study aimed to determine the prevalence of renal manifestations and associated factors in patients with SLE.
Materials and Methods: In this descriptive cross-sectional study carried out in 2022, 187 patients with SLE were evaluated. Demographic data, clinical, and laboratory findings were collected. Kidney function was assessed using the estimated glomerular filtration rate (eGFR). Logistic regression analysis was used to identify factors associated with mild to moderate kidney disease.
Results: 95.7% (n=179) of the patients were female. 34.2% (n=64) of patients had mild to moderate kidney disease. Patients with impaired kidney function were significantly older (p<0.001) and had higher mean levels of BUN, creatinine, and systolic blood pressure (p<0.001). Lupus nephritis was more common in this group (p=0.013). No significant differences were observed between the two groups regarding other demographic, clinical, or laboratory findings (p>0.05). In multivariate analysis, increased age and serum creatinine levels were independently associated with a higher risk of kidney disease (p<0.001).
Conclusion: The findings of current study showed that approximately one-third of SLE patients had evidence of mild to moderate renal impairment. Advanced age and elevated serum creatinine were identified as independent risk factors. Therefore, regular monitoring of kidney function in patients with SLE appears to be of critical importance.
Keywords: Erythematosus, Lupus nephritis, Chronic kidney disease, Rheumatology
Funding: This study did not have any funds.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Rafsanjan University of Medical Sciences approved the study (IR.RUMS.REC.1401.186).
Authors’ contributions:
- Conceptualization: Elahe Ahmadian
- Methodology: Zahra Kamiab, Mitra Abbasifard
- Data collection: Elahe Ahmadian, Seyed Mojtaba Heydari Khormizi
- Formal analysis: Zahra Kamiab, Mahdieh Jamshidi
- Supervision: Mitra Abbasifard
- Project administration: Mitra Abbasifard
- Writing - original draft: Elahe Ahmadian
- Writing - review & editing: Mitra Abbasifard, Zahra Kamiab, Mahdieh Jamshidi, Seyed Mojtaba Heydari Khormizi
Materials and Methods: In this descriptive cross-sectional study carried out in 2022, 187 patients with SLE were evaluated. Demographic data, clinical, and laboratory findings were collected. Kidney function was assessed using the estimated glomerular filtration rate (eGFR). Logistic regression analysis was used to identify factors associated with mild to moderate kidney disease.
Results: 95.7% (n=179) of the patients were female. 34.2% (n=64) of patients had mild to moderate kidney disease. Patients with impaired kidney function were significantly older (p<0.001) and had higher mean levels of BUN, creatinine, and systolic blood pressure (p<0.001). Lupus nephritis was more common in this group (p=0.013). No significant differences were observed between the two groups regarding other demographic, clinical, or laboratory findings (p>0.05). In multivariate analysis, increased age and serum creatinine levels were independently associated with a higher risk of kidney disease (p<0.001).
Conclusion: The findings of current study showed that approximately one-third of SLE patients had evidence of mild to moderate renal impairment. Advanced age and elevated serum creatinine were identified as independent risk factors. Therefore, regular monitoring of kidney function in patients with SLE appears to be of critical importance.
Keywords: Erythematosus, Lupus nephritis, Chronic kidney disease, Rheumatology
Funding: This study did not have any funds.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Rafsanjan University of Medical Sciences approved the study (IR.RUMS.REC.1401.186).
Authors’ contributions:
- Conceptualization: Elahe Ahmadian
- Methodology: Zahra Kamiab, Mitra Abbasifard
- Data collection: Elahe Ahmadian, Seyed Mojtaba Heydari Khormizi
- Formal analysis: Zahra Kamiab, Mahdieh Jamshidi
- Supervision: Mitra Abbasifard
- Project administration: Mitra Abbasifard
- Writing - original draft: Elahe Ahmadian
- Writing - review & editing: Mitra Abbasifard, Zahra Kamiab, Mahdieh Jamshidi, Seyed Mojtaba Heydari Khormizi
Type of Study: Research |
Subject:
Urology
Received: 2024/10/6 | Accepted: 2025/08/4 | Published: 2025/10/18
Received: 2024/10/6 | Accepted: 2025/08/4 | Published: 2025/10/18
References
1. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s principles of internal medicine, 19e. New York, NY, USA: Mcgraw-hill; 2015.
2. Firestein GS, Budd R, Gabriel SE, McInnes IB, O’Dell JR. Kelley and Firestein’s textbook of rheumatology e-book. Elsevier 2016.
3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82(5): 299–308.
4. Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus 2020; 29(9): 1011–20.
5. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers 2020; 6(1).
6. Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatology 2017; 56 (suppl_1): i3–13.
7. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 2020; 76(2): 265–81.
8. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol 2017; 12(5): 825–35.
9. Houssiau F. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15(10): 2694–704.
10. Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med 2021; 10(4): 670.
11. Davatchi F, Sandoughi M, Moghimi N, Jamshidi AR, Tehrani Banihashemi A, Zakeri Z. Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. Int J Rheum Dis 2016; (v; 19(11): 1056-62).
12. Davatchi F, Tehrani Banihashemi A, Gholami J, Faezi ST, Forouzanfar MH, Salesi M. The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 2009; (v; 28: 1267-74).
13. Moghimi N, Davatchi F, Rahimi E, Saidi A, Rashadmanesh N, Moghimi S. WHO-ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. Clin Rheumatol 2015 Mar.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al. A disease activity index for lupus patients. Arthritis Rheum 1992; 35(6): 630-40.
15. Hermansen ML, Sandholt B, Fuchs A, Sillesen H, Køber L, Kofoed KF. Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. Rheumatol 2018; 57(11): 1964–71.
16. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. A disease activity index for lupus patients. Arthritis Rheum 2000; 13(6): 406–8.
17. Mattos P, Santiago MB. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol 2012; 31(6): 897–905.
18. Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. Curr opin immunol 2016; 43: 32–8.
19. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dism 2020; 76(2): 265–81.
20. Liu Z, Davidson A. Taming lupus—a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18(6): 871–82.
21. Hocaoǧlu M, Valenzuela‐Almada MO, Dabit JY, Osei‐Onomah SA, Chevet B, Giblon RE. Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population‐Based Study Over Four Decades Using the Lupus Midwest Network. Arthritis Rheumatol 2023; 75(4): 567–73.
22. Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L, et al. The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev 2019; 18(7): 733–7.
23. Rabbani MA, Tahir MH, Siddiqui BK, Ahmad B, Shamim A, Shah SM, et al. Renal involvement in systemic lupus erythematosus in Pakistan. J Pak Med Assoc 2005; 55(8): 328.
24. Plantinga L, Lim SS, Patzer R, McClellan W, Kramer M, Klein M, et al. Incidence of end‐stage renal disease among newly diagnosed systemic lupus erythematosus patients: the Georgia Lupus Registry. Arthritis Care Res 2016; 68(3): 357–65.
25. Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al. Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 2018; 77(9): 1318–25.
26. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, et al. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology 2022; 61(11): 4335–43.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
